News

MedPage Today on MSN2d
CVS Drops Obesity Drug; Once-Weekly Growth Hormone; WeightWatchers' Bankruptcy
People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...
CNBC on MSN8d
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
GlobalData on MSN1d
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies
Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.
Seattle Times3d
Why patients are being forced to switch to a 2nd-choice obesity drug
Word spread quickly online about the change after Caremark ... employer clients paid for obesity drugs by 10% to 15% compared with the previous year. Advertising “CVS Caremark was able to ...
NBC Chicago8d
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
As part of the move, Caremark will also drop Eli Lilly's weight loss drug Zepbound from ... "In our view, the Novo/CVS deal does not represent the beginning of an obesity pricing war between ...